To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations unit:
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 211 21 03 80
Maria José Louro
Media relations assistant
Tel: (351) 211 21 02 00/40
Fax: (351) 211 21 03 80
Ahead of World AIDS Day on 1 December, the EMCDDA has released today a new toolkit offering countries the latest guidance on monitoring infectious diseases, such as HIV/AIDS and viral hepatitis, among people who inject drugs (PWID).
Sharing evidence to help prevent and reduce harm related to addiction is the focus of a workshop hosted by the EMCDDA in Lisbon this week. The two-day event, opening today, is organised by the European Agency for Health and Consumers (EACH), in collaboration with the European Commission.
A set of Council conclusions on improving the monitoring of drug supply in the European Union was adopted by the Economic and Financial Affairs Council meeting in Brussels today. The need to scale up the monitoring of illicit drug supply in Europe is an important component of the current EU drugs strategy (2013–20).
Ambassador Paul E. Simons, Executive Secretary of the Inter-American Drug Abuse Control Commission (CICAD) of the Organisation of American States (OAS) visits the EMCDDA today to discuss with the agency’s Director Wolfgang Götz perspectives for the next EMCDDA–CICAD work programme (2014–18).
The four winners of the 2013 EMCDDA scientific paper award will be honoured in Lisbon this week at the third annual award ceremony hosted by the EU agency. The winners — based in Germany, Austria, Norway and at the EMCDDA — will receive a non-monetary prize for their contributions on 7 November in the margins of the EMCDDA’s Scientific Committee meeting.
As of 28 October 2013, six cases of wound botulism have been reported in Norway among people who had injected heroin.
It is 20 years today since the EMCDDA’s founding regulation entered into force. Over this period, the agency has established strong mechanisms in Europe to carry out regular and sustained monitoring of developments in the drugs field.
EU drug markets, Cannabis production and markets and New heroin-assisted treatment – the three EMCDDA publications recognised among the ‘notable government documents 2012’ of the American Library Association.
EMCDDA Director Wolfgang Götz will be opening a workshop today in Zadar, Croatia, in his first official visit to the country since its accession to the EU in July 2013. The two-day workshop, which focuses on Croatia’s national drug monitoring system, is being organised by the European Commission’s Technical Assistance and Information and Exchange Instrument (TAIEX), in cooperation with the EMCDDA and the Office for Combating Drug Abuse of the Government of the Republic of Croatia (Reitox national focal point).
‘Analysing, interpreting and disseminating drug-related data to facilitate decision-making’ will be the focus of an innovative training course hosted by the EU drugs agency (EMCDDA) this week in Lisbon. Opening today and running until 2 October, the event is a thematic twinning initiative of the EU’s Cooperation Programme between Latin America and the European Union on Drugs Policies (COPOLAD).
The first EMCDDA week on ‘Measuring, understanding and responding to drug problems in Europe’ opens today in Lisbon. The initiative represents a new and integrated take on the usual format of the agency’s five yearly expert meetings, to date dedicated to each of the EMCDDA key epidemiological indicators.
The EMCDDA welcomes the European Commission’s proposal today to strengthen the EU’s response to new psychoactive substances (‘new drugs’). The proposal follows an unprecedented rise in the number of new drugs detected in Europe in recent years and a Commission review of the EU’s current legal mechanism for monitoring and acting on these new substances.
International experts convene in Swansea (UK) today to examine the latest scientific research in the rapidly-changing field of new drugs. The Second international conference on novel psychoactive substances is hosted by the College of Human and Health Sciences at Swansea University, in collaboration with Hertfordshire University and the EMCDDA.
Members of the European Parliament Committee on Civil Liberties, Justice and Home Affairs (LIBE) will visit the EU drugs agency (EMCDDA) on 18 and 19 July and hear why a sound evidence base is essential for effective policymaking and action in the drugs field.
Addiction is a global issue that costs many millions of lives each year and causes untold suffering. In a new report, released today to mark International day against drug abuse and illicit trafficking, the EU drugs agency (EMCDDA) looks at how far the science of addiction has come and how this knowledge can be used to help tackle the problem.
New psychoactive substances (NPS) have changed the nature of the global drugs market. The UK has taken the opportunity of its one-year presidency of the G8 to lead on tackling the threat of NPS. Published today is the G8’s statement of intent on collecting and sharing data in this area.
Leading European and international specialists will meet in Lisbon from 27–28 June to take stock of the global new drugs phenomenon. The Third international multidisciplinary forum on new drugs, organised by the EU drugs agency (EMCDDA), in cooperation with Europol, will gather over 100 participants from some 40 countries.
The EU drugs agency (EMCDDA) and the European Maritime Safety Agency (EMSA) will open their doors to the public this Thursday 20 June on the occasion of the inauguration of Praça Europa, the square on which the agencies are located in Lisbon’s Cais do Sodré area.
Record levels of treatment provision for Europe’s drug users are among the positive changes seen in the current European drug landscape, according to the European Drug Report 2013: Trends and developments published today by the EMCDDA in Lisbon. Yet, the agency warns that considerable challenges remain for treatment services.
Europe’s drugs problem is in a ‘state of flux’, with new threats emerging that challenge current models of policy and practice. This is according to the European Drug Report 2013: Trends and developments, published today by the EMCDDA in Lisbon. In its annual review, the agency describes positive developments in relation to the more established drugs, such as fewer new users of heroin, less injecting and declining use of cannabis and cocaine in some countries.
The number, type and availability of new drugs in Europe continued to increase in 2012, according to a report released today by the EMCDDA and Europol. Driven by globalisation, technological advancement and the Internet, an open market for new drugs has now developed which presents significant challenges to public health, law enforcement and policymaking.
Leading European and international experts will meet in Lisbon from 6–8 May to review the state of the art of a rapidly-developing scientific discipline known as ‘drug wastewater analysis’. The event, ‘Testing the waters: the first international multidisciplinary conference on illicit drugs and wastewater’, is being organised by the EMCDDA, in collaboration with: the EU-funded SEWPROF project; the Italian Mario Negri Institute; and the Norwegian Institute for Water Research.
The EMCDDA has reshaped the way in which it reports on Europe’s drugs problem. On 28 May, the agency will present its annual overview of the European drug situation in a new information package designed to be ‘more timely, interactive and interlinked’. Central to the package is the European Drug Report 2013: Trends and developments which replaces the former Annual report on the state of the drugs problem in Europe, traditionally published in the autumn. Released six months earlier, the shorter, graphic-rich report summarises the latest trends across the 27 EU Member States, Norway, Croatia and Turkey.
Today we are launching our latest publication in the field of prevention. ‘Drug prevention interventions targeting minority ethnic populations’ is a Thematic paper that comes as part of the agency’s monitoring of action 20 of the European Union drugs action plan 2009–12 on developing services for minority groups, including migrants. »
Europe has responded today to concerns over the use of the stimulant drug 4-methylamphetamine (4-MA) by subjecting it to ‘control measures and criminal penalties’ throughout the Union. The Decision of the Council of the EU was adopted in the final stage of the three-step legal procedure designed to respond to potentially threatening new psychoactive drugs entering the market.
The national drug policy of Ireland comes under the spotlight in the latest volume in the EMCDDA series of Drug policy profiles released today.
Drug trafficking is a highly profitable commercial activity and a core business for organised crime groups across Europe today. Understanding the reality of the European drug market requires a holistic approach, following the economic chain from production, via trafficking, to consumption. In today’s EU drug markets report, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol have joined forces to provide the first state-of-the-art overview of this market in its entirety.
Europe is entering an important new era in the supply and demand for illicit drugs — a development which is challenging current policies and responses. This is according to the first joint EU drug markets report from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol released today in Brussels.
Drug trafficking is a highly profitable commercial activity and remains a core business for organised crime groups across Europe today. Understanding the reality of the European drug market requires a holistic approach, following the economic chain from production, via trafficking, to consumption. Taking such an approach, two EU agencies — the EMCDDA and Europol — have joined forces to provide the first state-of-the-art overview of this market in its entirety. The EU drug markets report — a strategic analysis will be launched in Brussels on 31 January.
The EMCDDA and the First Faculty of Medicine of Charles University in Prague will be cooperating in training and research activities in the field of drugs in future, thanks to a Memorandum of Understanding (MoU) signed between the two parties today in the Czech capital.
The Lisbon-based Instituto Superior das Ciências do Trabalho e da Empresa (ISCTE-IUL) and the EU drugs agency (EMCDDA) are currently collaborating on their second summer school project entitled: 'Illicit drugs in Europe: supply, demand and public policies'. Registration opens today for the course which will take place in the Portuguese capital from 1–12 July 2013.
The use of illicit drugs and psychoactive medicines amongst drivers, particularly when combined with alcohol, is described today in a new report from the EMCDDA. The ‘state of the art’ review presents the results of the largest research project ever carried out in the EU on Driving under the influence of drugs, alcohol and medicines (the ‘DRUID’ project), which ran between 2006 and 2011.
This week, the EMCDDA is hosting three meetings in Lisbon on the topic of drugs and wastewater. Wastewater analysis is a rapidly developing scientific discipline with the potential for monitoring real-time population-level trends in illicit drug use. On 10 December, the results of an EMCDDA multicity project will be presented by an international consortium of researchers. »
João Goulão, Portuguese national drug coordinator and Head of the General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), was re-elected Chairman of the EMCDDA Management Board today for a second three-year term. Claude Gillard (Belgium), a founding member of the agency, was also re-elected today to the position of Vice-Chairman.